This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ASM journals
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Etlinger, H M
Right arrow Articles by Takacs, B
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Etlinger, H M
Right arrow Articles by Takacs, B

 Previous Article  |  Next Article 

Infect Immun. 1991 October; 59(10): 3498-3503

Ability of recombinant or native proteins to protect monkeys against heterologous challenge with Plasmodium falciparum.

H M Etlinger, P Caspers, H Matile, H J Schoenfeld, D Stueber and B Takacs

Central Research Units, F. Hoffmann LaRoche Ltd., Basel, Switzerland.

ABSTRACT

To circumvent problems associated with polymorphic vaccine candidates for Plasmodium falciparum malaria, we evaluated recombinant proteins representing sequences from relatively high conserved regions of the precursor to the major merozoite surface proteins, gp190, for their ability to protect Saimiri monkeys against malaria challenge. Recombinant proteins represented amino acid residues 147 to 321 (p190-1) or 147 to 321 and 1060 to 1195 (p190-3), and their efficacy was compared with that of native gp190 and its processed products. All antigens were derived from P. falciparum K1, a Thai isolate, while the challenge strain was Palo Alto (from Uganda, Africa), which contains, with the exception of the N-terminal 375 amino acids, which are almost identical to the K1 sequence, essentially the MAD-20 allelic form of gp190. By 12 days following challenge, each control monkey required drug treatment. Three monkeys injected with p190-3 required therapy, while one cleared the parasites without therapy. Two monkeys injected with p190-1 received therapy on day 14, while the remaining two cleared the parasites without therapy. Of four animals injected with native gp190, because of health reasons unrelated to malaria, one was not challenged with parasites and one was removed from the study 8 days after challenge when its parasitemia was 1.1% (parasitemias in control animals ranged from 4.3 to 9%); the remaining two cleared the parasites after maximum parasitemias of 0.45 and 0.53%. The highest levels of antiparasite antibody were produced by animals immunized with native gp190. There was a significant correlation between monkeys which did not require drug treatment and antiparasite antibody. These results may suggest that native gp190 and/or its processed products can provide excellent protection against heterologous challenge and that antibody is important for protection. The challenge for vaccine development is to identify the protective sequence(s).

Infect Immun. 1991 October; 59(10): 3498-3503




This article has been cited by other articles:

  • VALDERRAMA-AGUIRRE, A., QUINTERO, G., GOMEZ, A., CASTELLANOS, A., PEREZ, Y., MENDEZ, F., AREVALO-HERRERA, M., HERRERA, S. (2005). ANTIGENICITY, IMMUNOGENICITY, AND PROTECTIVE EFFICACY OF PLASMODIUM VIVAX MSP1 PV200L: A POTENTIAL MALARIA VACCINE SUBUNIT. Am J Trop Med Hyg 73: 16-24 [Abstract] [Full Text]  
  • Mello, K., Daly, T. M., Long, C. A., Burns, J. M., Bergman, L. W. (2004). Members of the Merozoite Surface Protein 7 Family with Similar Expression Patterns Differ in Ability To Protect against Plasmodium yoelii Malaria. Infect. Immun. 72: 1010-1018 [Abstract] [Full Text]  
  • Mello, K., Daly, T. M., Morrisey, J., Vaidya, A. B., Long, C. A., Bergman, L. W. (2002). A Multigene Family That Interacts with the Amino Terminus of Plasmodium MSP-1 Identified Using the Yeast Two-Hybrid System. Eukaryot Cell 1: 915-925 [Abstract] [Full Text]  
  • Pang, A. L. Y., Hashimoto, C. N., Tam, L. Q., Meng, Z. Q., Hui, G. S. N., Ho, W. K. K. (2002). In Vivo Expression and Immunological Studies of the 42-Kilodalton Carboxyl-Terminal Processing Fragment of Plasmodium falciparum Merozoite Surface Protein 1 in the Baculovirus-Silkworm System. Infect. Immun. 70: 2772-2779 [Abstract] [Full Text]  
  • Qian, F., Pan, W. (2002). Construction of a tetR-Integrated Salmonella enterica Serovar Typhi CVD908 Strain That Tightly Controls Expression of the Major Merozoite Surface Protein of Plasmodium falciparum for Applications in Human Vaccine Production. Infect. Immun. 70: 2029-2038 [Abstract] [Full Text]  
  • Parra, M., Hui, G., Johnson, A. H., Berzofsky, J. A., Roberts, T., Quakyi, I. A., Taylor, D. W. (2000). Characterization of Conserved T- and B-Cell Epitopes in Plasmodium falciparum Major Merozoite Surface Protein 1. Infect. Immun. 68: 2685-2691 [Abstract] [Full Text]  
  • Narum, D. L., Ogun, S. A., Thomas, A. W., Holder, A. A. (2000). Immunization with Parasite-Derived Apical Membrane Antigen 1 or Passive Immunization with a Specific Monoclonal Antibody Protects BALB/c Mice against Lethal Plasmodium yoelii yoelii YM Blood-Stage Infection. Infect. Immun. 68: 2899-2906 [Abstract] [Full Text]  
  • Egan, A. F., Blackman, M. J., Kaslow, D. C. (2000). Vaccine Efficacy of Recombinant Plasmodium falciparum Merozoite Surface Protein 1 in Malaria-Naive, -Exposed, and/or -Rechallenged Aotus vociferans Monkeys. Infect. Immun. 68: 1418-1427 [Abstract] [Full Text]  
  • Yang, S., Nikodem, D., A.Davidson, E., Gowda, D.C. (1999). Glycosylation and proteolyticprocessing of 70 kDa C-terminal recombinant polypeptides of Plasmodiumfalciparum merozoite surface protein 1 expressed in mammaliancells. Glycobiology 9: 1347-1356 [Abstract] [Full Text]  
  • Kang, Y., Calvo, P. A., Daly, T. M., Long, C. A. (1998). Comparison of Humoral Immune Responses Elicited by DNA and Protein Vaccines Based on Merozoite Surface Protein-1 from Plasmodium yoelii, a Rodent Malaria Parasite. J. Immunol. 161: 4211-4219 [Abstract] [Full Text]  
  • Matsumoto, S., Yukitake, H., Kanbara, H., Yamada, T. (1998). Recombinant Mycobacterium bovis Bacillus Calmette-Guerin Secreting Merozoite Surface Protein 1 (MSP1) Induces Protection against Rodent Malaria Parasite Infection Depending on MSP1-stimulated Interferon {gamma} and Parasite-specific Antibodies. JEM 188: 845-854 [Abstract] [Full Text]  
  • Perlaza, B. L., Arevalo-Herrera, M., Brahimi, K., Quintero, G., Palomino, J. C., Gras-Masse, H., Tartar, A., Druilhe, P., Herrera, S. (1998). Immunogenicity of Four Plasmodium falciparum Preerythrocytic Antigens in Aotus lemurinus Monkeys. Infect. Immun. 66: 3423-3428 [Abstract] [Full Text]  
  • Becker, S. I., Wang, R., Hedstrom, R. C., Aguiar, J. C., Jones, T. R., Hoffman, S. L., Gardner, M. J. (1998). Protection of Mice against Plasmodium yoelii Sporozoite Challenge with P. yoelii Merozoite Surface Protein 1 DNA Vaccines. Infect. Immun. 66: 3457-3461 [Abstract] [Full Text]  
  • Cavanagh, D. R., Elhassan, I. M., Roper, C., Robinson, V. J., Giha, H., Holder, A. A., Hviid, L., Theander, T. G., Arnot, D. E., McBride, J. S. (1998). A Longitudinal Study of Type-Specific Antibody Responses to Plasmodium falciparum Merozoite Surface Protein-1 in an Area of Unstable Malaria in Sudan. J. Immunol. 161: 347-359 [Abstract] [Full Text]  
  • Gowda, D. C., Gupta, P., Davidson, E. A. (1997). Glycosylphosphatidylinositol Anchors Represent the Major Carbohydrate Modification in Proteins of Intraerythrocytic Stage Plasmodium falciparum. J. Biol. Chem. 272: 6428-6439 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»